跳至主要内容
临床试验/IRCT20131012014988N8
IRCT20131012014988N8招募中Unknown

Evaluation of the effecacy and safety of Risdiplam and Nusinersen in patients with Spinal Muscular Atrophy ??(SMA)

Tabriz University of Medical Sciences0 个研究点目标入组 40 人开始时间: 待定最近更新:
适应症

试验速览

阶段
Unknown
状态
招募中
入组人数
40

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 10 years(—)
性别
All

入选标准

  • Definitive genetic diagnosis of homozygous gene mutation or deletion(5q SMA)
  • Patients with equal or less than 10 years old
  • SMN2 copy number is 2 to 4

排除标准

  • Active infection requiring systemic antibiotic or antiviral treatment up to 2 weeks after recovery
  • Existence of concomitant incurable diseases (history of asphyxia, seizures, severe liver, cardiovascular, and endocrine envolvement)
  • Liver failure (due to the possibility of increased drug levels) (Child Pugh class C)
  • receiving metformin (for risdiplam)
  • Lactation and pregnancy
  • History of recent eye diseases (uncontrolled glaucoma) (for Risdiplam)
  • Existence of severe kyphoscoliosis or corrective surgery (for Nocinersen)
  • Having a CNS shunt and CSF catheter (for Nocinersen)
  • History of bacterial meningitis (for nosinersen)

研究者

相似试验